Health economic evaluation of topical treatments for external anogenital warts - 20/09/24
Abstract |
Introduction |
No treatment hierarchy for external anogenital warts (AGW) is currently recommended, despite wide variations in the costs of available treatments. The aim of this study was to propose a treatment hierarchy based on a health economic analysis of local treatments for AGW from the perspective of the French health insurance system.
Methods |
Thirteen treatments and 73 treatment sequences were evaluated for AGW clearance and absence of AGW recurrence at 3 months of follow-up. The cost per treatment included the cost of consultations, drugs, medical procedures, and dressings. The time horizon was one year. The least expensive treatment was used as the reference treatment in the calculation of incremental cost-effectiveness ratios (ICERs). A two-line decision tree for treatment was constructed.
Results |
Podophyllotoxin 0.5% solution was the least expensive treatment. Compared to podophyllotoxin 0.5% solution, the most cost-effective treatment was surgical excision (ICER: €456.82) and the most cost-effective treatment sequence was podophyllotoxin 0.5% solution followed by 5-fluorouracil (5-FU) 5% cream.
Conclusion |
Considering the high risk of bias in the randomized controlled trials considered, the most cost-effective treatment sequence was podophyllotoxin 0.5% solution followed by 5-FU 5% cream.
Le texte complet de cet article est disponible en PDF.Keywords : Sexually transmitted infections, Anogenital warts, Cost-effectiveness analysis
Abbreviations : AGW, HPV, 5-FU, TCA, RCT, ICER
Plan
Vol 151 - N° 3
Article 103288- septembre 2024 Retour au numéro
Article précédent
- Changes in the gut microbiota of pseudoxanthoma elasticum patients
- M. Berard, K. Chassain, C. Méry, F. Gillaizeau, T. Carton, H. Humeau, N. Navasiolava, S. Rocour, L. Schurgers, M. Kempf, L. Martin
- Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm
- F. Poizeau, S. Leducq, L. Fardet, M. Beylot-Barry, Guillaume Chaby, M. Chastagner, F. Corgibet, L. Gouillon, N. Jouan, D. Jullien, A. Acher, F. Amatore, J.-M. Amici, H. Aubert, F. Aubin, N. Beneton, D Bouilly, A.-C. Bursztejn, C. Buzenet, M. Chamaillard-Pujol, J. Charles, A.-C. Cottencin-Charriere, B. Duval Modeste, A. Fauconneau, A.-C. Fougerousse, C. Girard, C. Goujon, A. Khemis, Y. Le Ru, C. Lepelley-Dupont, E. Mahé, X. Marcellin, C. Nicolas, V. Pallure, J. Parier, N. Quiles, P.-E. Stoebner, M. Tauber, A. Vermersch, M. Viguier, A.P. Villani, O. Chosidow, B. Guillot, Psoriasis Research Group (GRPso) and the Centre of Evidence of the French Society of Dermatology
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?